- Zacks•4 days ago
Jazz Pharmaceuticals Public Limited Company (JAZZ) announced that its phase III study, evaluating JZP-110 has completed patient enrollment.
- PR Newswire•5 days agoJazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy
DUBLIN, Nov. 28, 2016 /PRNewswire/ -- Jazz Pharmaceuticals plc (JAZZ) today announced that patient enrollment has been completed in its Phase 3 study evaluating JZP-110 in excessive sleepiness (ES) associated with narcolepsy. The Phase 3 narcolepsy study was a double-blind, placebo-controlled, multiple-center study evaluating the safety and efficacy of JZP-110 in the treatment of ES in adult patients with narcolepsy. The study enrolled 240 patients. The co-primary endpoints were the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale. These are validated endpoints, commonly used in clinical trials, that measure the ability to stay awake and the severity of excessive sleepiness, respectively, in patients.
JAZZ : Summary for Jazz Pharmaceuticals plc - Ordi - Yahoo Finance
Jazz Pharmaceuticals Public Limited Company (JAZZ)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||102.32 x 100|
|Ask||126.26 x 100|
|Day's Range||101.80 - 103.40|
|52 Week Range||95.80 - 160.00|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||17.89|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|